ReviewBone marrow transplantation2014
Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers.
Review in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03689465 (A Comparison of PTCy-ATG and ATG Strategy in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Comparison of PTCy-ATG and ATG Strategy in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis
Who cites it
13 citing papers in PubMed, 35 citations in OpenAlex.
- Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study.BMC medicine · 2019Trial
- Comparison of the clinical outcomes between NIMA-mismatched and NIPA-mismatched haploidentical hematopoietic stem cell transplantation for patients with hematological malignancies.Bone marrow transplantation · 2021Article
- Haploidentical Stem Cell Transplantation for Acute Myeloid Leukemia: Current Therapies, Challenges and Future Prospective.Frontiers in oncology · 2021Review
- [Advances in hematopoietic stem cell transplantation for hematological disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
- Update of the "Beijing Protocol" haplo-identical hematopoietic stem cell transplantation.Bone marrow transplantation · 2019Review
- Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation.Frontiers of medicine · 2019Review
- Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation.Frontiers in immunology · 2019Review
- Relationship of Cell Compositions in Allografts with Outcomes after Haploidentical Transplantation for Acquired Severe Aplastic Anemia: Effects of CD34Chinese medical journal · 2018Article
- Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant.Haematologica · 2017Article
- [Haploidentical transplantation for the treatment of intermediate- or high- risk acute myeloid leukemia in first complete remission: guideline and practice].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- [Strategy to improve clinical outcome of unmanipulated haploidentical stem cell transplantation without in vitro T cell depletion].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?Journal of hematology & oncology · 2016Review
- Improving the clinical outcome of unmanipulated haploidentical blood and marrow transplantation.Bone marrow transplantation · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research on the different mechanisms for crossing HLA barriers has progressed over the past 10 years. General outlines have come into view for a solution to this issue and are often presented as 'haploidentical SCT' immunology. In this review, we discuss several mechanisms that have recently been described in ex vivo and in vivo settings that can either avoid GVHD or promote hematopoietic reconstitution in haploidentical settings. The host and donor T-cell responses to allogeneic HLA molecules are a fundamental obstacle to the successful application of haploidentical transplantation, which results in unacceptably high incidences of GVHD and graft rejection. Thus, the T-cell response is a central factor in the establishment of a novel haploidentical transplant protocol with superior outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.